

# Induction of tolerance through early introduction of peanut in high-risk children

**Submission date**  
19/12/2006

**Recruitment status**  
No longer recruiting

Prospectively registered

Protocol

**Registration date**  
04/04/2007

**Overall study status**  
Completed

Statistical analysis plan

Results

**Last Edited**  
29/01/2016

**Condition category**  
Injury, Occupational Diseases, Poisoning

Individual participant data

## Plain English summary of protocol

Background and study aims

The number of children in the Western World that have a peanut allergy has doubled in the past ten years and the allergy is now also found in Africa and Asia. It is the leading cause of food allergy related anaphylaxis (acute allergic reaction) and death. The allergy develops early in life and is generally life-long. Studies have suggested that the earlier peanuts are introduced to a child's diet, the less likely they are to develop an allergy to them. This study looks at whether giving children that are considered at higher risk of developing a peanut allergy (as they are already allergic to eggs or have severe eczema) earlier in life reduces the risk of them actually becoming allergic to peanuts.

Who can participate?

Children aged between 4 months and 11 months that have an egg allergy, severe eczema, or both.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group are fed a peanut-containing snack-food at least three times each week until they are 5 years old. Those in the second group avoid eating food containing peanuts until they are 5 years old. All the children are followed up to see which ones develop a peanut allergy.

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

Evelina Children's Hospital, London (UK)

When is the study starting and how long is it expected to run for?

November 2006 to July 2013

Who is funding the study?

1. US National Institute of Allergy & Infectious Diseases
2. Immune Tolerance Network (USA)

3. Food Allergy Initiative (USA)
4. Food Standards Agency (UK)

Who is the main contact?  
Professor Gideon Lack  
info@leapstudy.co.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Gideon Lack

**Contact details**  
Evelina Children's Hospital  
Guy's & St. Thomas' NHS Foundation Trust  
Lambeth Palace Road  
London  
United Kingdom  
SE1 7EH  
+44 (0)20 7188 9784  
info@leapstudy.co.uk

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00329784

**Protocol serial number**  
ITN032AD Lack

## Study information

**Scientific Title**  
Induction of tolerance through early introduction of peanut in high-risk children

**Acronym**  
LEAP (Learning Early About Peanut allergies)

**Study objectives**  
This study will evaluate whether early avoidance or exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are at high risk as determined by allergy to eggs or severe eczema.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**

St. Marys Research Ethics Committee, 23/10/2006, ref: 04/Q0413/13

**Primary study design**

Interventional

**Study design**

Randomised controlled single-site trial

**Study type(s)**

Prevention

**Health condition(s) or problem(s) studied**

Peanut allergy, peanut hypersensitivity, eczema, egg hypersensitivity, food hypersensitivity

**Interventions**

Participants assigned to the peanut consumption group will be fed at least 6 g of peanut protein per week, distributed over at least three meals per week during study participation. The preferred peanut source will be Bamba, however, peanut butter may be substituted. Participants assigned to the peanut avoidance group will avoid exposure to peanut protein during study participation.

**Intervention Type**

Supplement

**Primary outcome(s)**

The proportion of participants with peanut allergy at 60 months of age.

**Key secondary outcome(s)**

1. Effect of peanut consumption on other allergy outcomes
2. Safety of peanut consumption among study participants
3. Immunologic mechanisms by which consumption of peanut may induce tolerance to peanuts

**Completion date**

01/07/2013

**Eligibility****Key inclusion criteria**

1. Children greater than four months and less than 11 months of age
2. Have had solid foods introduced successfully into their diet
3. Egg allergy, severe eczema or both

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

4 Months

**Upper age limit**

11 Months

**Sex**

All

**Key exclusion criteria**

1. Clinically significant chronic illness, except for eczema or recurrent wheeze
2. Positive skin prick test for peanut allergen with a wheal diameter of greater than 4 mm
3. Previous or current consumption of peanut
4. Previous allergic reaction to peanut
5. Sibling or other household member who is allergic to peanut
6. Certain other immunological criteria

**Date of first enrolment**

29/11/2006

**Date of final enrolment**

01/07/2013

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Evelina Children's Hospital**

London

United Kingdom

SE1 7EH

## **Sponsor information**

**Organisation**

Immune Tolerance Network for National Institute of Allergy and Infectious Diseases

**ROR**

<https://ror.org/043z4tv69>

# Funder(s)

## Funder type

Government

## Funder Name

US National Institute of Allergy & Infectious Diseases

## Funder Name

Immune Tolerance Network (USA)

## Funder Name

Food Allergy Initiative

## Alternative Name(s)

FAI

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Trusts, charities, foundations (both public and private)

## Location

United States of America

## Funder Name

Food Standards Agency

## Alternative Name(s)

The Food Standards Agency, FSA

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	26/02/2015		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes